尿路性器癌患者におけるポリエチレングリコール沈降物補体消費試験によるCirculating Immune Complexes の測定

Abstract

健康人18例のCICの平均は2.7%で, SDは±3.0%であり, この成績より2SDに近い10%以下を正常値とした.泌尿器科的良性疾患患者9例のそれは2.9±2.7%であり, いずれの症例ほ正常値であった.腎細胞癌患者9例での陽性率は33%, 前立腺癌患者16例のそれは19%と比較的高値を示したが, 膀胱腫瘍患者21例の陽性率は5%と低く, さらに腎盂尿管腫瘍患者3例においては1例も陽性を認めなかった.なお, 腎細胞癌患者9例についての検討で, 摘出標本の大きさとCIC値との間に相関は得られずむしろ逆相関の傾向を認めた

Circulating immune complexes (CIC) were detected and quantitated in 49 patients with urological malignant diseases (9 cases of renal cell cancer, 3 cases of renal pelvic and ureter cancer, 21 cases of bladder cancer and 16 cases of prostatic cancer), 9 patients with urological benign diseases and in normal subjects by the polyethylene-glycol precipitation complement consumption test (PEG-CC test). The average CIC level was 2.7 +/- 3.0% in 18 normal subjects and the normal range was less than 10% of the CIC level. CIC level of patients with renal cell cancer was 14.3 +/- 20.1%, being elevated in 3 of the 9 patients, that of patients with renal pelvic and ureter cancer was 4.7 +/- 4.6%, being within the normal range in 3 cases, that of patients with bladder cancer was 4.7 +/- 4.4%, being elevated in 1 of 21 patients, and that of patients with prostatic cancer was 8.9 +/- 15.4%, being elevated in 3 of 16 patients. In urological malignant diseases such as renal cell cancer and prostatic cancer the CIC values were relatively high.